Advanced Clear Cell Renal Cell Carcinoma
17
6
10
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
11.8%
2 terminated out of 17 trials
0.0%
-86.5% vs benchmark
18%
3 trials in Phase 3/4
0%
1 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (17)
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
177LuPSMA in Renal Cell Carcinoma
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma
A Clinical Research of CD70-targeted CAR-NKT Cells (CGC738) Therapy in RCC
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
Avelumab, Palbociclib and Axitinib in Advanced RCC
A Clinical Study of 6MW3211 in Patients With Renal Cancer